Drug review process advancement and required manufacturer and contract research oraganization responses

• Published in: Journal of Toxicologic Pathology 2024, Vol.37 (2), p.45-53
• Main Authors: Takayuki Anzai, Glenn J.Myatt, Frances Hall, Brenda Finney, Kenshi Nakagawa, Hijiri Iwata, Reo Anzai, Anne Dickinson, Matthew Freer, Dai Nakae, Hiroshi Onodera, Takaaki Matsuyama
• Format: Article
• Language: Japanese
• ISSN: 0914-9198

[Abstract]: The United States Senate passed the "FDA Modernization Act 2.0." on September 29, 2022. Although the effectiveness of this Bill, which aims to eliminate the mandatory use of laboratory animals in new drug development, is limited, it represents a significant trend that will change the shape of drug applications in the United States and other countries. However, pharmaceutical companies have not taken major steps towards the complete elimination of animal testing from the standpoint of product safety, where they prioritize patient safety. Nonetheless, society is becoming increasingly opposed to animal testing, and efforts will be made to use fewer animals and conduct fewer animal tests as a natural and reasonable response. These changes eventually alter the shape of new drug applications. Based on the assumption that fewer animal tests will be conducted or fewer animals will be used in testing, this study explored bioinformatics and new technologies as alternatives to compensate for reduced information and provide a picture of how future new drug applications may look. The authors also discuss the directions that pharmaceutical companies and nonclinical contract research organizations should adopt to promote the replacement, reduction, and refinement of animals used in research, teaching, testing, and exhibitions.